Amir K. Jaffer, MD

Amir K. Jaffer, MD
Medical Director, The Internal Medicine Preoperative Assessment Consultation and Treatment (IMPACT) Center and the Anticoagulation Clinic, Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic

Daniel J. Brotman, MD
Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic

Nkem Chukwumerije, MD
Kaiser Permanente Medical Center, Panorama, CA

Address: Amir K. Jaffer, MD, Department of General Internal Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: jaffera@ccf.org

Dr. Jaffer has indicated that he has received grant or research support from Astra Zeneca, serves as a consultant for Aventis and Astra Zeneca, and is on the speakers’ bureau of Aventis.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Amir K. Jaffer, MD
Medical Director, The Internal Medicine Preoperative Assessment Consultation and Treatment (IMPACT) Center and the Anticoagulation Clinic, Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic

Daniel J. Brotman, MD
Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic

Nkem Chukwumerije, MD
Kaiser Permanente Medical Center, Panorama, CA

Address: Amir K. Jaffer, MD, Department of General Internal Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: jaffera@ccf.org

Dr. Jaffer has indicated that he has received grant or research support from Astra Zeneca, serves as a consultant for Aventis and Astra Zeneca, and is on the speakers’ bureau of Aventis.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Amir K. Jaffer, MD
Medical Director, The Internal Medicine Preoperative Assessment Consultation and Treatment (IMPACT) Center and the Anticoagulation Clinic, Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic

Daniel J. Brotman, MD
Section of Hospital and Preoperative Medicine, Department of General Internal Medicine, The Cleveland Clinic

Nkem Chukwumerije, MD
Kaiser Permanente Medical Center, Panorama, CA

Address: Amir K. Jaffer, MD, Department of General Internal Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: jaffera@ccf.org

Dr. Jaffer has indicated that he has received grant or research support from Astra Zeneca, serves as a consultant for Aventis and Astra Zeneca, and is on the speakers’ bureau of Aventis.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.